Valuation: KalVista Pharma

Market Cap 1.44B 1.26B 1.16B 1.07B 2.04B 136B 2.07B 13.9B 5.41B 67.33B 5.4B 5.28B 233B P/E 2024
-2.46x
P/E 2025 -5.3x
Enterprise Value 1.42B 1.24B 1.15B 1.06B 2.02B 135B 2.05B 13.75B 5.35B 66.58B 5.34B 5.22B 230B EV / Sales 2024
-
EV / Sales 2025 10.9x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 month 23.27
Extreme 23.27
23.39
Current year 23.27
Extreme 23.27
23.39
1 year 23.27
Extreme 23.27
23.39
3 years 23.27
Extreme 23.27
23.39
5 years 23.27
Extreme 23.27
23.39
10 years 23.27
Extreme 23.27
23.39
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/11/2016
Chief Executive Officer 61 06/03/2024
President - 11/06/2026
Director TitleAgeSince
Chairman - 11/06/2026

Financials

2024 2025
Net sales - 73.62M 64.42M 59.37M 55.03M 104M 6.99B 106M 712M 277M 3.45B 276M 270M 11.92B
Net income -127M -111M -102M -94.67M -180M -12.02B -183M -1.22B -476M -5.93B -475M -465M -20.5B -164M -144M -132M -123M -233M -15.59B -237M -1.59B -618M -7.7B -617M -603M -26.6B
Net Debt -203M -178M -164M -152M -288M -19.27B -293M -1.96B -764M -9.51B -762M -746M -32.88B -16.01M -14.01M -12.91M -11.97M -22.71M -1.52B -23.08M -155M -60.2M -750M -60.1M -58.79M -2.59B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A